Zevra Therapeutics, Inc. (ZVRA) Tops Q2 EPS by 16c, beats revenue

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) reported Q2 EPS of ($0.15), $0.16 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $3.07 million.

For earnings history and earnings-related data on Zevra Therapeutics, Inc. (ZVRA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c